[Edaily Reporter Kwon Oh Seok ] TOMATOSYSTEM Co.,Ltd.(393210), a company specializing in artificial intelligence (AI) software and digital healthcare, announced in a regulatory filing on the 6th that CEOs Jo Gil-ju and Lee Kang-chan recently made consecutive on-market purchases of the company’s shares. (Photo courtesy of TOMATOSYSTEM Co.,Ltd.) CEO Jo purchased 10,000 shares of the company’s stock on the open market on the 30th of last month, while CEO Lee also purchased 10,000 shares in three separate transactions between July 31 and August 4. Starting with these purchases, the company plans to continuously review additional share buybacks by management, taking into comprehensive consideration market conditions and corporate value. The company explained that this share repurchase demonstrates the management’s confidence in the company’s mid- to long-term growth potential and corporate value through direct action. It further elaborated that this move reflects the company’s commitment to further strengthening responsible management and conveying confidence in its growth vision to shareholders and stakeholders, particularly since transitioning to a co-CEO system earlier this year with the appointment of CEO Lee Kang-chan. TOMATOSYSTEM Co.,Ltd. is expanding its market competitiveness beyond the public, education, and financial sectors into the manufacturing sector, focusing on its AI-based digital transformation (DX) solutions and UI/UX development platform businesses. In particular, the company is aggressively expanding its AI business led by “eXBuilder6 AIGen,” a generative AI-based UI development solution, while continuously enhancing the market competitiveness of its next-generation UI/UX development platform, “eXBuilder6.” At the same time, the company is actively pursuing its digital healthcare business in the U.S. Centered on the NOVA platform, which targets insurance companies and medical institutions, it is accelerating its expansion into the global market by offering innovative services that combine AI with healthcare. The company’s strategy is to build a foundation for sustainable growth based on the stable growth of its existing core businesses and the expansion of new ventures.
During the era of massive railroad and telecommunications network construction in the United States, companies poured enormous amounts of capital into expanding railroad and fiber-optic networks in an…
The families of owners at some mid-sized and small companies—facing the threat of delisting due to so-called “penny stocks” with share prices below 1,000 won—are actively buying back shares. Analysts …
It has been revealed that DuChemBio Co.,LTD.(176750)accounted for 96.3% of the domestic production value of radiopharmaceuticals used to diagnose Alzheimer’s disease last year. As domestic prescriptio…
